Want to see MMED full AI Analyst Report?
MMED Stock Chart & Stats
$14.44
--
Market closed
$14.44
--
Day’s Range― - ―
52-Week Range$10.65 - $20.48
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$4.29B
Enterprise Value$3.98B
Total Cash (Recent Filing)$298.00M
Total Debt (Recent Filing)$145.00M
Price to Earnings (P/E)―
Beta0.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding280,842,830
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)0.94
Price to Sales (P/S)1.09
P/FCF Ratio-8.06
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.69
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda180.92
Forecast
1Y Price Target
$21.40Price Target Upside48.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue surged 104.9% in 2026, indicating strong product adoption and rapid market penetration. Durable top-line momentum supports scale economics, funds continued R&D and commercialization, and provides the foundation for potential margin expansion if the company improves cost conversion.
European Product LaunchThe commercial rollout in Europe of MiniMed 780G and MiniMed Go integrated with Abbott's Instinct sensors is a structural expansion of the product ecosystem. It broadens the addressable market, deepens distribution, and supports recurring sensor revenues and stickiness over the medium term.
Conservative Balance SheetA conservatively financed balance sheet with modest debt relative to a large equity base and rising assets provides financing flexibility. Low leverage helps absorb cash burn during scale-up, supports investment in commercialization, and reduces near-term solvency risk.
Bears Say
Widening Net LossesNet losses expanding to -$331M in 2026 show the company has yet to translate revenue growth into profitability. Persistent large losses can erode capital, limit reinvestment capacity, and increase dependence on external funding, raising long‑term dilution and execution risk if margins do not improve.
Deteriorating Cash GenerationOperating cash flow turned negative and free cash flow plunged, signaling rising cash burn despite revenue growth. Sustained negative cash generation increases funding risk, may constrain R&D or commercialization spend, and could force dilutive financing or cost reductions that hinder growth execution.
Negative ROE & Thin MarginsNegative ROE and only marginal operating profitability indicate capital is not generating acceptable returns. Weak returns reduce the company's ability to self-fund growth, increase sensitivity to reimbursement and competitive pressures, and make sustained value creation contingent on meaningful margin improvement.
MMED FAQ
What was MiniMed Group, Inc.’s price range in the past 12 months?
MiniMed Group, Inc. lowest stock price was $10.65 and its highest was $20.48 in the past 12 months.
What is MiniMed Group, Inc.’s market cap?
MiniMed Group, Inc.’s market cap is $4.29B.
When is MiniMed Group, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MiniMed Group, Inc.’s earnings last quarter?
Currently, no data Available
Is MiniMed Group, Inc. overvalued?
According to Wall Street analysts MiniMed Group, Inc.’s price is currently Undervalued.
Does MiniMed Group, Inc. pay dividends?
MiniMed Group, Inc. does not currently pay dividends.
What is MiniMed Group, Inc.’s EPS estimate?
MiniMed Group, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MiniMed Group, Inc. have?
MiniMed Group, Inc. has 280,842,830 shares outstanding.
What happened to MiniMed Group, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MiniMed Group, Inc.?
Currently, no hedge funds are holding shares in MMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MiniMed Group, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.40 (48.20% Upside)
$21.40 (48.20% Upside)
Blogger Sentiment
Bullish
MMED Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 37.8%
Last 30 Days ▲ 37.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-9.34%
Trailing 12-Months
Asset Growth
10.21%
Trailing 12-Months
Company Description
MiniMed Group, Inc.
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.
MMED Company Deck
MMED Earnings Call
Q4 2026
0:00 / 0:00
MMED Stock 12 Month Forecast
Average Price Target
$21.40
▲(48.20% Upside)
Addus Homecare
―
Option Care Health
―
Brookdale Senior Living
―
National Healthcare
―
Aveanna Healthcare Holdings
―
Ownership Overview
0.73% Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
98.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---